Effectiveness of Integrated Care on Delaying Progression of stage 3-4 Chronic Kidney Disease in Rural Communities of Thailand (ESCORT study): a cluster randomized controlled trial

Table 2 Mean levels of clinical outcomes, laboratory parameters, and medications between intervention group and control group

Variables	Mean level during follow-up		Mean difference (coefficient)	95% CI	P-value
Variables	Control (n = 208)	Intervention (n = 234)	Mean difference (coefficient)	95% CI	P-value
BMI (kg/m²)	24.8 ± 0.2	24.9 ± 0.2	0.49	(−0.3)–1.2	0.22
eGFR (CKD-EPI, ml/min/1.73 m²)	39.9 ± 2.8	42.4 ± 1.5	2.74	0.7–4.8	0.009
Serum Creatinine (mg/dl)	1.6 ± 0.1	1.5 ± 0.1	−0.10	(−0.2)–(−0.02)	0.02
Systolic BP (mmHg)	120 ± 2.3	125 ± 1.9	5.37	3.4–7.3	0.01
Diastolic BP (mmHg)	73 ± 1.3	74 ± 1.8	1.23	0.3–2.2	0.01
Hemoglobin (g/dl)	11.3 ± 0.2	11.2 ± 0.3	0.45	0.36	0.42
Serum bicarbonate (mEq/L)	21.5 ± 1.7	24.5 ± 1.1	2.84	2.4–3.3	0.001
HbA1C in diabetics (%) ^a	7.9 ± 0.4	7.3 ± 0.2	−0.57	(−0.9)–(−0.2)	0.001
LDL-C (mg/dL)	108 ± 5	107 ± 16	−1.09	(−5.6)–3.4	0.63
Triglyceride (mg/dL)	209 ± 22	192 ± 15	−18.15	(−35.5)–(−0.8)	0.04
Urine protein-creatinine ratio (mg/g)	260 ± 84	336 ± 55	11.42	(−97)–119	0.84
24-h urine Na (mg/day) ^a	3682 ± 635	2931 ± 309	−739.0	(−1136)–(−343)	0.001
24-h urine nPNA (g/kg/day)	0.91 ± 0.1	0.84 ± 0.02	0.10	(−0.2)–(0.001)	0.049

GEE analyses were used to determine mean differences over time of clinical outcomes and laboratory parameters between the two groups
Data was shown as means (standard deviation) for continuous variables
Abbreviations: GEE generalized estimating equation
^aDiffrences already exist at baseline

ISSN: 1471-2369